Abu Dhabi Sleep Apnea (ADSA) Study

Sleep Apnoea Clinical Trial

— ADSA  

Official title:

Abu Dhabi Sleep Apnea (ADSA) Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02403141
• Other study ID #: IREC020
• Status: Active, not recruiting
• Phase: N/A
• First received: March 25, 2015
• Last updated: March 1, 2017
• Start date: March 2015
• Est. completion date: March 2017

Study information

• Verified date: March 2017
• Source: Imperial College London Diabetes Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Obstructive sleep apnoea (OSA) is a common medical problem which, despite increasing awareness, remains under-diagnosed. There is a close association between OSA and obesity; 60-70% of patients diagnosed with OSA are either obese or overweight [1]. OSA is also very common among patients with type 2 diabetes. Type 2 Diabetes Mellitus (T2DM) has reached epidemic status in the Gulf region. OSA worsens insulin resistance and leads to weight gain through sleep disturbance [2]. Several mechanisms have been proposed for the associations of OSA with diabetes and obesity [3]. At present there is little available information regarding the prevalence of OSA in the UAE, the relationship with T2DM and obesity, and the impact of OSA on health outcomes in the Emirati population. This research will explore these relationships and inform public health decisions regarding diagnostic pathways, service provision and treatment protocols.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1400
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

Participants aged between 18-64 years old. Both Gender male and female.

Exclusion Criteria:

Paediatrics below the age of 18. Any participant who is unable to take part

Related Conditions & MeSH terms

• Apnea
• Sleep Apnea Syndromes
• Sleep Apnoea

Intervention

Other:
• Questionnaire

Locations

Country	Name	City	State
United Arab Emirates	Imperial College London Diabetes Centre	Abu Dhabi

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London Diabetes Centre

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary objective (Establishing the prevalence of OSA in the study population.)	Establishing the prevalence of OSA in the study population.	3 months